David Drewry

David Drewry

SGC UNC

Drewry

David Drewry

(919) 962-5349

Biography

David Drewry is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy. Drewry enjoys running, reading and relaxing with his family at local restaurants, the movie theater or in the kitchen playing board games.

2022

Target 2035 - update on the quest for a probe for every protein.

Müller S, Ackloo S, Al Chawaf A, Al-Lazikani B, Antolin A, Baell JB, Beck H, Beedie S, Betz UAK, Bezerra GA, Brennan PE, Brown D, Brown PJ, Bullock AN, Carter AJ, Chaikuad A, Chaineau M, Ciulli A, Collins I, Dreher J, Drewry D, Edfeldt K, Edwards AM, Egner U, Frye SV, Fuchs SM, Hall MD, Hartung IV, Hillisch A, Hitchcock SH, Homan E, Kannan N, Kiefer JR, Knapp S, Kostic M, Kubicek S, Leach AR, Lindemann S, Marsden BD, Matsui H, Meier JL, Merk D, Michel M, Morgan MR, Mueller-Fahrnow A, Owen DR, Perry BG, Rosenberg SH, Saikatendu KS, Schapira M, Scholten C, Sharma S, Simeonov A, Sundström M, Superti-Furga G, Todd MH, Tredup C, Vedadi M, von Delft F, Willson TM, Winter GE, Workman P, Arrowsmith CH

RSC Med Chem. 2022-1-27 . 13(1):13-21 .doi: 10.1039/d1md00228g

PMID: 35211674

2021

NUAK family kinase 2 is a novel therapeutic target for prostate cancer.

Fu W, Zhao MT, Driver LM, Schirmer AU, Yin Q, You S, Freedland SJ, DiGiovanni J, Drewry DH, Macias E

Mol Carcinog. 2021-11-24 . .doi: 10.1002/mc.23374

PMID: 34818445

Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors.

Kalogirou AS, East MP, Laitinen T, Torrice CD, Maffuid KA, Drewry DH, Koutentis PA, Johnson GL, Crona DJ, Asquith CRM

Molecules. 2021-9-29 . 26(19): .doi: 10.3390/molecules26195911

PMID: 34641454

Design and Development of a Chemical Probe for Pseudokinase Ca2+/calmodulin-Dependent Ser/Thr Kinase.

Russ N, Schröder M, Berger BT, Mandel S, Aydogan Y, Mauer S, Pohl C, Drewry DH, Chaikuad A, Müller S, Knapp S

J Med Chem. 2021-9-20 . .doi: 10.1021/acs.jmedchem.1c00845

PMID: 34543009

Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer.

Schirmer AU, Driver LM, Zhao MT, Wells CI, Pickett JE, O'Bryne SN, Eduful BJ, Yang X, Howard L, You S, Devi GR, DiGiovanni J, Freedland SJ, Chi JT, Drewry DH, Macias E

Mol Ther. 2021-8-24 . .doi: 10.1016/j.ymthe.2021.08.029

PMID: 34450249

Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.

Drewry DH, Annor-Gyamfi JK, Wells CI, Pickett JE, Dederer V, Preuss F, Mathea S, Axtman AD

J Med Chem. 2021-8-1 . .doi: 10.1021/acs.jmedchem.1c00440

PMID: 34333981

Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes.

Eduful BJ, O'Byrne SN, Temme L, Asquith CRM, Liang Y, Picado A, Pilotte JR, Hossain MA, Wells CI, Zuercher WJ, Catta-Preta CMC, Zonzini Ramos P, Santiago AS, Couñago RM, Langendorf CG, Nay K, Oakhill JS, Pulliam TL, Lin C, Awad D, Willson TM, Frigo DE, Scott JW, Drewry DH

J Med Chem. 2021-7-15 . .doi: 10.1021/acs.jmedchem.0c02274

PMID: 34264658

NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.

Matossian MD, Elliott S, Van Hoang T, Burks HE, Wright MK, Alzoubi MS, Yan T, Chang T, Wathieu H, Windsor GO, Hartono AB, Lee S, Zuercher WJ, Drewry DH, Wells C, Kapadia N, Buechlein A, Fang F, Nephew KP, Collins-Burow BM, Burow ME

Breast Cancer Res Treat. 2021-7-1 . .doi: 10.1007/s10549-021-06295-4

PMID: 34196902

Crowdsourced mapping of unexplored target space of kinase inhibitors.

Cichońska A, Ravikumar B, Allaway RJ, Wan F, Park S, Isayev O, Li S, Mason M, Lamb A, Tanoli Z, Jeon M, Kim S, Popova M, Capuzzi S, Zeng J, Dang K, Koytiger G, Kang J, Wells CI, Willson TM, Oprea TI, Schlessinger A, Drewry DH, Stolovitzky G, Wennerberg K, Guinney J, Aittokallio T

Nat Commun. 2021-6-3 . 12(1):3307 .doi: 10.1038/s41467-021-23165-1

PMID: 34083538

Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells.

Matossian MD, Elliott S, Rhodes LV, Martin EC, Hoang VT, Burks HE, Zuercher WJ, Drewry DH, Collins-Burow BM, Burow ME

Oncol Lett. 2021-3-30 . 21(5):380 .doi: 10.3892/ol.2021.12641

PMID: 33777204